Skip links

Respiratory Diseases Vaccines Markets, 2020-2025 by Infection, Type, Age Group, Geography and the Impact of Covid-19 –

The “Global Respiratory Diseases Vaccines Market by Infection, Type, Age Group, Geography and the Impact of Covid-19 (2020-2025)” report has been added to’s offering.

“Global Respiratory Diseases Vaccines Market by Infection, Type, Age Group, Geography and the Impact of Covid-19 (2020-2025)”Tweet this

The market is driven by factors such as the increasing prevalence of respiratory diseases, a growing number of vaccines under trial, etc. While the lack of inadequate delivery infrastructure and limited consumer awareness are some of the restraining factors. Increasing R&D expenditure and the increasing availability of vaccines through various collaborations is creating opportunities for market growth.

Respiratory Disease Vaccine Market: Introduction

Respiratory disease affects the lungs and other parts of the respiratory system. In addition to tobacco smoke, other risk factors include air pollution, occupational chemicals and dust, and frequent lower respiratory infections during childhood.

Chronic respiratory diseases (CRDs) are diseases of the airways and other structures of the lung. Some of the most common is chronic obstructive pulmonary disease (COPD), asthma, occupational lung diseases, and pulmonary hypertension.

Treatments for each chronic respiratory disease vary and the ideal solution is the reduction and avoidance of risk factors. Neither asthma nor chronic obstructive pulmonary disease (COPD) can be cured but treatments can reduce symptoms, prevent escalation, and improve quality of life.

Population protection by vaccination against infections has been one of the major achievements of public health and is of considerable importance in controlling respiratory diseases.

The report offers a comprehensive evaluation of the global respiratory disease vaccine market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.

The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry. The report includes in-depth market analysis using Porter’s 5 force model. The impact of Covid-19 on the market is also featured in the report.

Key Topics Covered:

1 Introduction

1.1 Objectives of the study

1.2 Market Definition

1.3 Currency

1.4 Years Considered for the study

1.5 Language

1.6 Key Benefits for Shareholders

2 Research Methodology

2.1 Research Process

2.2 Data Collection and Validation

2.3 Market Assessment

2.4 Assumptions of the Study

2.5 Limitations of the Study

3 Executive Summary

4 Market Overview

4.1 Introduction

4.2 Global Respiratory Disease Vaccine Market Size, by Geography

5 Market Dynamics

5.1 Drivers

5.2 Restraints

5.3 Opportunities

5.4 Trends

6 Market Analysis

6.1 Porter’s Five Forces Analysis

6.2 Impact of COVID-19

7 Global Respiratory Disease Vaccine Market, By Infection

7.1 Introduction

7.2 Influenza Virus

7.3 Pertussis

7.4 Streptococcus Pneumoniae

7.5 Tuberculosis

8 Global Respiratory Disease Vaccine Market, By Type

8.1 Bacterial Vaccine

8.2 Combination Vaccine

8.3 Viral Vaccine

9 Global Respiratory Disease Vaccine Market, By Age Group

9.1 Adolescent Vaccination

9.2 Adult Vaccination

9.3 Infant Vaccination

10 Americas Respiratory Disease Vaccine Market

10.1 Argentina

10.2 Brazil

10.3 Canada

10.4 Mexico

10.5 United States

11 Europe, Middle East & Africa Respiratory Disease Vaccine Market

11.1 France

11.2 Germany

11.3 Italy

11.4 Netherlands

11.5 Qatar

11.6 Russia

11.7 Saudi Arabia

11.8 South Africa

11.9 Spain

11.10 United Arab Emirates

11.11 United Kingdom

12 Asia-Pacific Respiratory Disease Vaccine Market

12.1 Australia

12.2 China

12.3 India

12.4 Indonesia

12.5 Japan

12.6 Malaysia

12.7 Philippines

12.8 South Korea

12.9 Thailand

13 Competitive Scenario

13.1 Merger & Acquisition

13.2 Agreement, Collaboration, & Partnership

13.3 New Product Launch & Enhancement

13.4 Investment & Funding

13.5 Award, Recognition, & Expansion

14 Company Profiles

14.1 AstraZeneca

14.2 Bavarian Nordic

14.3 Bayer AG

14.4 Bio Farma

14.5 Dynavax Technologies Corporation

14.6 Emergent BioSolutions, Inc.

14.7 GlaxoSmithKline plc

14.8 Merck & Co., Inc.

14.9 Pfizer Inc.

14.10 Sanofi S.A.

14.11 Seqirus USA Inc.

For more information about this report visit

Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630

Leave a comment